Movement Alert|Veracyte Intraday Rise 5.67%, shares rebound after post-earnings selloff and analyst target cuts

Market Focus01:31

On November 19, Veracyte rose 5.67% in Regular Trading, trading at $25.54/share, with turnover of $14.98 million.

The latest publicly available catalyst is a rebound following the company’s recent post-earnings volatility: Veracyte previously reported third-quarter adjusted EPS of $0.51 and revenue of $151.8 million, both above consensus, but narrowed full-year revenue guidance to $590 million-$593 million from $590 million-$596 million, which had triggered a sharp selloff.

Subsequently, several brokers cut their price targets to $35, including Leerink, UBS and Guggenheim, while maintaining a more cautious stance on the shares. The current rise appears to reflect stabilization after that reset in expectations rather than a new fundamental announcement on the day.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment